Drug Profile

TH 1901

Alternative Names: Peptide-Curcumin Conjugate TH1901; TH1901

Latest Information Update: 26 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Theratechnologies
Class Antineoplastics; Drug conjugates; Peptide drug conjugates
Mechanism of Action Apoptosis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Suspended Cancer

Most Recent Events

22 Mar 2024 TH 1901 is available for licensing as of 22 Mar 2024. https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/sortilin
22 Mar 2024 Suspended - Preclinical for Cancer in Canada (unspecified route)
20 May 2020 Pharmacodynamics data from a preclinical study in Cancer presented at the American Association for Cancer Research virtual annual meeting (AACR-2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com